SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is experiencing significant market interest following a series of strategic expansion announcements, including a major commitment to building autonomous vehicle charging infrastructure and new partnerships to integrate ride-hailing services. The community is actively debating the stock's long-term valuation versus its recent price volatility, with many investors highlighting substantial insider buying and institutional backing as signs of a potential bottom.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is generating significant market activity as investors weigh the impact of its recent acquisition of Astria Therapeutics against high short interest and expectations for upcoming earnings. The community is actively discussing the company's valuation floor and potential for a buyout, while monitoring clinical data readouts for navenibart and broader pipeline progress.

Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1983 and is headquartered in Seattle, WA.

Perspective Therapeutics Inc

Perspective Therapeutics is gaining significant market attention following a strategic equity offering that extends its cash runway and strengthens its balance sheet to support ongoing clinical milestones into 2027. Investors and community members are actively debating the impact of this capital raise, with many interpreting the participation of high-profile institutional entities as a vote of confidence in the company's proprietary radiopharmaceutical platform and its potential as a prime buyout target.

Lyft, Inc. engages in the provision and management of an online social rideshare community platform. It offers access to a network of shared bikes and scooters for shorter rides and first mile and last-mile legs of multimodal trips, information about nearby public transit routes, and Lyft Rentals to offer riders a view of transportation options when planning any trip. The company was founded by Marcus Cohn, John Zimmer, Rajat Suri, Matt van Horn, and Logan D. Green on March 5, 2007 and is headquartered in San Francisco, CA.

Lyft Inc - Ordinary Shares Cls A

Lyft Inc

Lyft is currently a focal point for investors as the community debates its valuation and potential for an acquisition or share buyback following a recent earnings report that sparked significant volatility. Traders are closely tracking the stock's performance relative to Uber, with intense discussions around the impact of autonomous vehicle partnerships and the company's long-term profitability metrics.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending amid intense debate over the proposed Digital Asset Market Clarity Act, with the community split between bullish sentiment fueled by institutional partnership speculation and skepticism from those concerned about price manipulation. Traders are closely monitoring the token's correlation with broader market movements and its ability to maintain support levels as discussions around global adoption and potential regulation intensify.

Bakkt, Inc. is building the backbone of next-generation financial infrastructure. The company provides solutions that enable institutional participation in the digital asset economy, spanning Bitcoin, tokenization, stablecoin payments, and AI-driven finance. Bakkt was founded in 2018 and is headquartered in New York, NY.

Bakkt Inc. - Ordinary Shares - Class A

Bakkt Holdings Inc

Bakkt is capturing significant trader attention as investors monitor its recent strategic acquisition of DTR and potential integration with institutional digital asset infrastructure. While many in the community remain divided between optimistic technical momentum plays and concerns over share dilution, active discussions are focused on how the company's evolving neobanking strategy and upcoming investor events may influence its performance in the shifting regulatory landscape.

Semtech Corp. engages in the manufacture and supply of analog and mixed signal semiconductor products for high-end consumer, enterprise computing, communications, and industrial equipment. The firm operates through the following business segments: Protection, Signal Integrity, and Wireless & Sensing. It offers signal integrity, protection, wireless and sensing, and power and high-reliability products. The company was founded in 1960 and is headquartered in Camarillo, CA.

Semtech Corp.

Semtech is facing intense volatility and downward pressure following significant guidance adjustments, fueling a fierce battle between retail bulls hunting for a short squeeze and bearish traders citing concerns over inventory and market headwinds. Investors are currently hyper-focused on the company's long-term potential in data center connectivity and AI infrastructure versus the immediate technical damage caused by recent, sharp price declines.

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

CytomX Therapeutics Inc

CytomX Therapeutics is trending heavily after announcing positive Phase 1 expansion data for its EpCAM PROBODY ADC, Varsetatug Masetecan, in patients with late-line colorectal cancer. The community is actively debating the stock's significant price surge and high volume, with investors weighing the clinical trial success against concerns about potential future dilution and the company's financial results.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital is trending as investors closely watch for the announcement of a major tenant for its digital infrastructure projects, with sentiment currently driven by a mix of high-stakes anticipation and skepticism regarding management's project timelines. The community is actively debating the company's growth potential versus concerns over potential dilution and the lack of a finalized contract, while many traders remain focused on the stock's high volatility and its correlation with broader data center and energy sector momentum.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate Inc. is seeing a surge in investor attention driven by strong momentum in its ADHD therapeutic pipeline, specifically the upcoming PDUFA decision for CTx-1301 and anticipation surrounding US patent developments. The community is actively discussing the stock's low-float setup, recent insider and institutional positioning, and the potential for a significant revaluation as the company advances toward its commercial launch.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Promising Pharmaceutical Stocks To Keep An Eye On - March 16th

Eli Lilly and Company, CytomX Therapeutics, Pfizer, HCW Biologics, and AbbVie are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks...

Best Medical Stocks To Watch Today - March 16th

Eli Lilly and Company, CytomX Therapeutics, and UnitedHealth Group are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly...

CytomX Therapeutics (NASDAQ:CTMX) Stock Price Expected to Rise, HC Wainwright Analyst Says

HC Wainwright boosted their target price on CytomX Therapeutics from $10.00 to $17.00 and gave the company a "buy" rating in a research report on Monday...

Mid-Cap CytomX Therapeutics' Colorectal Cancer Data Fuels Stock Rally

CytomX Therapeutics stock jumps in premarket trading after Phase 1 data for Varseta-M showed tumor responses in colorectal cancer patients.read more...

CytomX Therapeutics (NASDAQ:CTMX) Rating Increased to Overweight at JPMorgan Chase & Co.

JPMorgan Chase & Co. upgraded shares of CytomX Therapeutics from a "neutral" rating to an "overweight" rating and boosted their target price for the company from $7.00 to $12.00 in a research note on...

CytomX Therapeutics (NASDAQ:CTMX) Sets New 12-Month High - Here's What Happened

CytomX Therapeutics (NASDAQ:CTMX) Sets New 1-Year High - Still a Buy...

Biotech Breakthroughs and Capital Moves Drive a Busy Market Week

A wave of biotech developments, strategic financings, and emerging-technology announcements shaped market narratives this week, highlighting how innovation across biopharma, AI-driven automation, energy technology, and crypto finance continues to drive investor attention. $CTMX, $NVDA, $HCWB, $KBLB, $CYN, $BMNR, $CLIK, $CIIT, $AIRS, $DFLI

CytomX Therapeutics Q4 Earnings Call Highlights

CytomX Therapeutics (NASDAQ:CTMX) outlined updated Phase 1 dose expansion results for its EpCAM-targeting Probody antibody-drug conjugate (ADC) varsetatug masetecan (Varseta-M, Varseta ) during a...

CytomX Therapeutics (CTMX) Reports Q4 Loss, Misses Revenue Estimates

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -175.00% and -90.98%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

<ul class="summary-bullets"><li>The trial, started in April 2024, involved 93 advanced late-line metastatic colorectal cancer patients (CRC).</li><li>&nbsp;Across all dose levels, 88% of patients showed signs of disease control.</li><li>The company plans to engage with the FDA later this year on a potential registrational trial for the therapy.</li></ul>CytomX Therapeutics, Inc. (CTMX) on Monday announced encouraging early results from its Phase 1 expansion study of varsetatug masetecan (Varseta-M) in patients with late-line metastatic colorectal cancer (CRC).&nbsp;The data, as of January 16, indicated the antibody-drug conjugate is showing meaningful response rates across higher dose levels.&nbsp;Following the results,&nbsp;<a href="https://stocktwits.com/symbol/CTMX">CytomX Therapeutics stock</a> traded over 54% in Monday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock changed to ‘extremely bullish’ from ‘bullish’ territory the previous day. Message volume shifted to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">Promising Early Efficacy Signals In Phase 1 Study&nbsp;</h2>The CTMX-2051-101 trial, which began in April 2024, included 93 patients with advanced colorectal cancer who had already received multiple treatments. Out of these 56 could be assessed for how well the treatment worked.Participants received increasing doses of 7.2 mg/kg, 8.6 mg/kg, or 10 mg/kg every three weeks. Treatment responses improved as the dose increased. 6% of patients responded at 7.2 mg/kg, 20% at 8.6 mg/kg, and 32% at 10 mg/kg. Overall, 88% of patients across all doses experienced some level of disease control.CytomX plans to present additional Phase 1 data at medical meetings later in 2026. The company will engage with the FDA mid-year to discuss registrational trial design for Varseta-M monotherapy in advanced CRC.<h2 class="st-heading-2">Financial Performance: Revenue Declines As Collaboration Milestones End</h2>Revenue fell 44.8% year-on-year (YoY) to $76.2 million from $138.1 million in 2025, largely due to the completion of Bristol Myers Squibb collaboration obligations and slower recognition from Moderna, Astellas, and Regeneron partnerships.&nbsp;Operating expenses dropped 12.8% YoY to $98.6 million, with R&amp;D costs decreasing to $68.7 million following restructuring and strategic pipeline focus. CytomX closed 2025 with $137.1 million in cash, cash equivalents, and investments, providing a runway into Q2 2027.&nbsp;CTMX stock has gained over 642% in the last 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alibaba-consolidating-ai-empire-signaling-the-next-phase-of-monetization-push/cZ32wVrRIf0">Alibaba Is Reportedly Consolidating Its AI Empire – Signaling The Next Phase Of Monetization Push</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the CytomX Therapeutics logo is displayed on the screen of a tablet.

Why CTMX Stock Is Soaring 54% Pre-Market Today? 

CytomX Therapeutics reported promising Phase 1 expansion results for Varseta-M in late-line metastatic colorectal cancer.

Equity

CytomX Therapeutics reported promising Phase 1 expansion results for Varseta-M in late-line metastatic colorectal cancer.


$CTMX Q4 &#39;25 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.22 down -195.65% YoY
• Reported revenue of $0.66M down -98.26% YoY
• CytomX expects existing capital to fund operations into Q2 2027 and aims to align with the FDA in 2026 on a potential registrational study for Varseta-M monotherapy in advanced late-line CRC.

Stocktwits

 Q4 '25 Earnings Results & Recap

• Reported GAAP EPS of -$0.22 down -195.65% YoY
• Reported revenue of $0.66M down -98.26% YoY
• CytomX expects existing capital to fund operations into Q2 2027 and aims to align with the FDA in 2026 on a potential registrational study for Varseta-M monotherapy in advanced late-line CRC.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Up 5%

Down 5%

Show me the results

Which direction is the next 5% move for the S&amp;P 500?

Which direction is the next 5% move for the S&P 500?

Stocktwits Polls

CytomX Therapeutics' stock is surging after revealing compelling Phase 1 expansion data for Varseta-M, a potential new treatment for late-line colorectal cancer.

Many investors fear potential dilution following CytomX Therapeutics' announcement of a $250M common stock offering, which could impact recent price gains.

A wave of bearish sentiment and short-selling interest is emerging, with traders predicting a significant price correction after the stock's parabolic move.

Traders are noting the stark contrast between the stock's rally and its disappointing Q4 earnings miss, with significantly lower revenue and higher-than-expected losses.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.10	--	--	N/A
Q4 '25	-$0.09	-$0.33	-253.53%	MISSED
Q3 '25	-$0.05	-$0.09	-82.50%	MISSED
Q2 '25	-$0.06	$0.00	100.00%	BEAT
Q1 '25	$0.12	$0.27	116.43%	BEAT

CTMX
CytomX Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest CTMX News

CTMXCytomX Therapeutics Inc